Which has higher valuation and earnings, TVRD or RVPH?

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tvardi Therapeutics N/A N/A -$18.21M -$2.79 N/A Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A

Is TVRD or RVPH more profitable?

Tvardi Therapeutics' return on equity of -145.40% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Reviva Pharmaceuticals N/A -391.58% -119.08%

Do analysts recommend BFRI or RVPH?

Reviva Pharmaceuticals has a consensus price target of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better valuation and earnings, RVPH or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Reviva Pharmaceuticals N/A N/A -$19.86M -$1.85 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is RVPH or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Reviva Pharmaceuticals N/A -391.58% -119.08% Polyrizon N/A N/A N/A

Reviva Pharmaceuticals (RVPH) Competitors

$0.48 0.00 (0.00%)

As of 02:58 PM Eastern

Compare

RVPH vs. TVRD, TXMD, AYTU, BFRI, and PLRZ

Should you buy Reviva Pharmaceuticals stock or one of its competitors? Reviva Pharmaceuticals's main competitors and comparable companies include Tvardi Therapeutics (TVRD), TherapeuticsMD (TXMD), Aytu BioPharma (AYTU), Biofrontera (BFRI), and Polyrizon (PLRZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$2.79	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 5 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 0 mentions for Reviva Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.97 beat Reviva Pharmaceuticals' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
Reviva Pharmaceuticals	Neutral

Tvardi Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 922.73%. Reviva Pharmaceuticals has a consensus target price of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Tvardi Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -145.40% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

Tvardi Therapeutics beats Reviva Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

Reviva Pharmaceuticals (NASDAQ:RVPH) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, TherapeuticsMD had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 1 mentions for TherapeuticsMD and 0 mentions for Reviva Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.89 beat Reviva Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
TherapeuticsMD	Very Positive

TherapeuticsMD has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
TherapeuticsMD	$3.02M	8.28	-$570K	$0.02	108.00

Reviva Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Reviva Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals presently has a consensus price target of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Reviva Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Aytu BioPharma currently has a consensus target price of $10.75, suggesting a potential upside of 440.20%. Reviva Pharmaceuticals has a consensus target price of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aytu BioPharma had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Aytu BioPharma and 0 mentions for Reviva Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.93 beat Reviva Pharmaceuticals' score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Positive
Reviva Pharmaceuticals	Neutral

Aytu BioPharma has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Aytu BioPharma has higher revenue and earnings than Reviva Pharmaceuticals. Aytu BioPharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.32	-$13.56M	-$4.58	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Summary

Aytu BioPharma and Reviva Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Biofrontera had 6 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 6 mentions for Biofrontera and 0 mentions for Reviva Pharmaceuticals. Biofrontera's average media sentiment score of 0.70 beat Reviva Pharmaceuticals' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
Reviva Pharmaceuticals	Neutral

Reviva Pharmaceuticals has a consensus price target of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Biofrontera has higher revenue and earnings than Reviva Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$46.18M	0.38	-$10.54M	-$0.45	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Summary

Biofrontera beats Reviva Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Polyrizon?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Reviva Pharmaceuticals presently has a consensus target price of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 2 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 2 mentions for Polyrizon and 0 mentions for Reviva Pharmaceuticals. Polyrizon's average media sentiment score of 0.94 beat Reviva Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Polyrizon	Positive

Reviva Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, meaning that its share price is 239% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Polyrizon's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Polyrizon	N/A	N/A	N/A

Summary

Reviva Pharmaceuticals beats Polyrizon on 6 of the 11 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVPH vs. The Competition

Export

Metric	Reviva Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.29M	$12.44B	$7.16B	$14.34B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-0.26	792.10	273.41	25.32
Price / Sales	N/A	763.25	674.51	98.42
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	0.32	10.40	10.38	6.20
Net Income	-$19.86M	$2.83B	$3.49B	$358.18M
7 Day Performance	-10.86%	-3.28%	-2.17%	-1.58%
1 Month Performance	-5.88%	0.80%	-0.37%	-3.60%
1 Year Performance	-94.44%	3.62%	19.18%	5.95%

Reviva Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVPH Reviva Pharmaceuticals	1.5797 of 5 stars	$0.48 flat	$53.33 +11,011.1%	-94.6%	$6.29M	N/A	N/A	5
TVRD Tvardi Therapeutics	3.694 of 5 stars	$1.91 -0.3%	$18.00 +844.9%	-94.6%	$25.80M	$7.14M	N/A	80	News Coverage Analyst Upgrade
TXMD TherapeuticsMD	1.5198 of 5 stars	$2.12 -5.4%	N/A	+94.6%	$24.53M	$3.02M	106.00	420	Positive News
AYTU Aytu BioPharma	2.2523 of 5 stars	$2.24 +1.3%	$10.75 +380.3%	-15.3%	$23.62M	$66.38M	N/A	160
BFRI Biofrontera	1.0559 of 5 stars	$1.57 -2.8%	N/A	+61.7%	$23.39M	$41.71M	N/A	70	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. TVRD, TXMD, AYTU, BFRI, and PLRZ

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Reviva Pharmaceuticals compare to Biofrontera?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Reviva Pharmaceuticals (RVPH) Competitors

RVPH vs. TVRD, TXMD, AYTU, BFRI, and PLRZ

How does Reviva Pharmaceuticals compare to Tvardi Therapeutics?

Which has higher valuation and earnings, TVRD or RVPH?

Do insiders & institutionals hold more shares of TVRD or RVPH?

Does the media prefer TVRD or RVPH?

Do analysts prefer TVRD or RVPH?

Which has more volatility & risk, TVRD or RVPH?

Is TVRD or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to TherapeuticsMD?

Does the media refer more to RVPH or TXMD?

Which has higher earnings and valuation, RVPH or TXMD?

Is RVPH or TXMD more profitable?

Which has more volatility & risk, RVPH or TXMD?

Do insiders and institutionals hold more shares of RVPH or TXMD?

Do analysts rate RVPH or TXMD?

Summary

How does Reviva Pharmaceuticals compare to Aytu BioPharma?

Is AYTU or RVPH more profitable?

Do analysts recommend AYTU or RVPH?

Do institutionals & insiders hold more shares of AYTU or RVPH?

Does the media refer more to AYTU or RVPH?

Which has more risk and volatility, AYTU or RVPH?

Which has stronger valuation and earnings, AYTU or RVPH?

Summary

How does Reviva Pharmaceuticals compare to Biofrontera?

Do institutionals and insiders hold more shares of BFRI or RVPH?

Does the media prefer BFRI or RVPH?

Do analysts recommend BFRI or RVPH?

Which has better earnings & valuation, BFRI or RVPH?

Which has more volatility and risk, BFRI or RVPH?

Is BFRI or RVPH more profitable?

Summary

How does Reviva Pharmaceuticals compare to Polyrizon?

Do institutionals & insiders hold more shares of RVPH or PLRZ?

Do analysts prefer RVPH or PLRZ?

Does the media refer more to RVPH or PLRZ?

Which has more volatility and risk, RVPH or PLRZ?

Which has better valuation and earnings, RVPH or PLRZ?

Is RVPH or PLRZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH vs. The Competition

Reviva Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools